Skip to main content
padlock icon - secure page this page is secure

Free Content Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua kouté, Côte d’Ivoire

Download Article:

Objectives  To test the hypothesis that Artesunate–mefloquine paediatric (AS+MEF) is as effective as Artemether–lumefantrine (AL) in treating acute uncomplicated malaria in children.

Methods  In an open label, randomized controlled clinical trial, children aged 6–59 months were randomized to receive AS+MEF or AL. Both drug regimens were given for 3 days, and follow‐up was for 28 days. The primary endpoint was the 28‐day cure rate and was defined as proportion of patients with PCR‐corrected cure rate after 28 days of follow‐up.

Results  One hundred and fifty‐six patients with confirmed uncomplicated P. falciparum malaria were randomly assigned to receive AS+MEF (n = 77) or AL (n = 79). PCR‐corrected day 28 cure rates for per protocol (PP) populations were 99% for AS+MEF and 97% (P = 1) for AL. For the intention to treat (ITT) population, cure rates were 96% for AS+MEF and 92% (P = 0.49) for AL. Both regimens were well tolerated.

Conclusion  AS+MEF is as effective as AL, and both combinations were efficacious and safe.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Language: English

Document Type: Research Article

Affiliations: 1:  Malaria Department, Institut Pasteur, Abidjan, Côte d’Ivoire, West Africa 2:  Anonkoua-koute Health Centre, Abidjan, Côte d’Ivoire, West Africa

Publication date: March 1, 2011

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more